



# Toxicological Profile for Mirex and Chlordecone

October 2020



U.S. Department of Health and Human Services  
Agency for Toxic Substances and Disease Registry

## **DISCLAIMER**

Use of trade names is for identification only and does not imply endorsement by the Agency for Toxic Substances and Disease Registry, the Public Health Service, or the U.S. Department of Health and Human Services.

## FOREWORD

This toxicological profile is prepared in accordance with guidelines\* developed by the Agency for Toxic Substances and Disease Registry (ATSDR) and the Environmental Protection Agency (EPA). The original guidelines were published in the *Federal Register* on April 17, 1987. Each profile will be revised and republished as necessary.

The ATSDR toxicological profile succinctly characterizes the toxicologic and adverse health effects information for these toxic substances described therein. Each peer-reviewed profile identifies and reviews the key literature that describes a substance's toxicologic properties. Other pertinent literature is also presented, but is described in less detail than the key studies. The profile is not intended to be an exhaustive document; however, more comprehensive sources of specialty information are referenced.

The focus of the profiles is on health and toxicologic information; therefore, each toxicological profile begins with a relevance to public health discussion which would allow a public health professional to make a real-time determination of whether the presence of a particular substance in the environment poses a potential threat to human health. The adequacy of information to determine a substance's health effects is described in a health effects summary. Data needs that are of significance to the protection of public health are identified by ATSDR.

Each profile includes the following:

- (A) The examination, summary, and interpretation of available toxicologic information and epidemiologic evaluations on a toxic substance to ascertain the levels of significant human exposure for the substance due to associated acute, intermediate, and chronic exposures;
- (B) A determination of whether adequate information on the health effects of each substance is available or in the process of development to determine levels of exposure that present a significant risk to human health of acute, intermediate, and chronic health effects; and
- (C) Where appropriate, identification of toxicologic testing needed to identify the types or levels of exposure that may present significant risk of adverse health effects in humans.

The principal audiences for the toxicological profiles are health professionals at the Federal, State, and local levels; interested private sector organizations and groups; and members of the public.

This profile reflects ATSDR's assessment of all relevant toxicologic testing and information that has been peer-reviewed. Staffs of the Centers for Disease Control and Prevention and other Federal scientists have also reviewed the profile. In addition, this profile has been peer-reviewed by a nongovernmental panel and was made available for public review. Final responsibility for the contents and views expressed in this toxicological profile resides with ATSDR.



Patrick N. Breyse, Ph.D., CIH  
Director, National Center for Environmental Health and  
Agency for Toxic Substances and Disease Registry  
Centers for Disease Control and Prevention



Christopher M. Reh, Ph.D.  
Associate Director  
Agency for Toxic Substances and Disease Registry  
Centers for Disease Control and Prevention

### \*Legislative Background

The toxicological profiles are developed under the Comprehensive Environmental Response, Compensation, and Liability Act of 1980, as amended (CERCLA or Superfund). CERCLA section 104(i)(1) directs the Administrator of ATSDR to "...effectuate and implement the health related authorities" of the statute. This includes the preparation of toxicological profiles for hazardous substances most commonly found at facilities on the CERCLA National Priorities List (NPL) and that pose the most significant potential threat to human health, as determined by ATSDR and the EPA. Section 104(i)(3) of CERCLA, as amended, directs the Administrator of ATSDR to prepare a toxicological profile for each substance on the list. In addition, ATSDR has the authority to prepare toxicological profiles for substances not found at sites on the NPL, in an effort to "...establish and maintain inventory of literature, research, and studies on the health effects of toxic substances" under CERCLA Section 104(i)(1)(B), to respond to requests for consultation under section 104(i)(4), and as otherwise necessary to support the site-specific response actions conducted by ATSDR.

## VERSION HISTORY

Date	Description
October 2020	Final toxicological profile released
May 2019	Draft for public comment toxicological profile released
August 1995	Final toxicological profile released

## CONTRIBUTORS & REVIEWERS

### CHEMICAL MANAGER TEAM

Obaid Faroon, D.V.M., Ph.D.

ATSDR, Office of Innovation and Analytics,  
Toxicology Section, Atlanta, GA

David W. Wohlers, Ph.D.

Lisa Ingerman, Ph.D., DABT

Laura McIlroy, B.S.

SRC, Inc., North Syracuse, NY

### REVIEWERS

#### **Interagency Minimal Risk Level Workgroup:**

Includes ATSDR; National Center for Environmental Health (NCEH); National Institute for Occupational Safety and Health (NIOSH); U.S. Environmental Protection Agency (EPA); National Toxicology Program (NTP).

#### **Additional reviews for science and/or policy:**

ATSDR, Office of Community Health and Hazard Assessment; ATSDR, Office of Capacity Development and Applied Prevention Science; ATSDR, Office of Science; NCEH, Division of Laboratory Science; NCEH, Division of Environmental Health Science and Practice; EPA, National Center for Environmental Assessment.

### PEER REVIEWERS

1. Rogene Henderson, Ph.D., Applied Life Sciences and Toxicology, Lovelace Respiratory Research Institute, 2425 Ridgecrest Dr. SE, Albuquerque, New Mexico
2. Lucio Costa, PharmD., Department of Environmental and Occupational Health Sciences, Department of Neurological Surgery, University of Washington, Seattle, WA, USA and Department of Clinical and Experimental Medicine, University of Parma, Parma, Italy
3. Luc Multigner, M.D., Ph.D., Directeur de Recherche Inserm, Inserm U1085 – IRSET, Institut de Recherche sur la santé, l'environnement et le travail, 9 Avenue du Professeur Léon Bernard, Rennes and Faculté de Médecine, Campus de Fouillol, Pointe à Pitre Cedex, Guadeloupe

These experts collectively have knowledge of toxicology, chemistry, and/or health effects. All reviewers were selected in conformity with Section 104(I)(13) of the Comprehensive Environmental Response, Compensation, and Liability Act, as amended.

ATSDR scientists review peer reviewers' comments and determine whether changes will be made to the profile based on comments. The peer reviewers' comments and responses to these comments are part of the administrative record for this compound.

The listing of peer reviewers should not be understood to imply their approval of the profile's final content. The responsibility for the content of this profile lies with ATSDR.

## CONTENTS

DISCLAIMER .....	ii
FOREWORD .....	iii
VERSION HISTORY .....	v
CONTRIBUTORS & REVIEWERS .....	vi
CONTENTS .....	vii
LIST OF FIGURES .....	ix
LIST OF TABLES .....	x
CHAPTER 1. RELEVANCE TO PUBLIC HEALTH .....	1
1.1 OVERVIEW AND U.S. EXPOSURES .....	1
1.2 SUMMARY OF HEALTH EFFECTS .....	1
1.3 MINIMAL RISK LEVELS (MRLs) .....	9
CHAPTER 2. HEALTH EFFECTS .....	13
2.1 INTRODUCTION .....	13
2.2 DEATH .....	78
2.3 BODY WEIGHT .....	79
2.4 RESPIRATORY .....	80
2.5 CARDIOVASCULAR .....	81
2.6 GASTROINTESTINAL .....	82
2.7 HEMATOLOGICAL .....	83
2.8 MUSCULOSKELETAL .....	84
2.9 HEPATIC .....	84
2.10 RENAL .....	88
2.11 DERMAL .....	89
2.12 OCULAR .....	90
2.13 ENDOCRINE .....	91
2.14 IMMUNOLOGICAL .....	93
2.15 NEUROLOGICAL .....	93
2.16 REPRODUCTIVE .....	97
2.17 DEVELOPMENTAL .....	100
2.18 OTHER NONCANCER .....	104
2.19 CANCER .....	105
2.20 GENOTOXICITY .....	109
2.21 MECHANISMS OF ACTION .....	113
CHAPTER 3. TOXICOKINETICS, SUSCEPTIBLE POPULATIONS, BIOMARKERS, CHEMICAL INTERACTIONS .....	121
3.1 TOXICOKINETICS .....	121
3.1.1 Absorption .....	121
3.1.2 Distribution .....	124
3.1.3 Metabolism .....	129
3.1.4 Excretion .....	131
3.1.5 Physiologically Based Pharmacokinetic (PBPK)/Pharmacodynamic (PD) Models .....	135
3.1.6 Animal-to-Human Extrapolations .....	135
3.2 CHILDREN AND OTHER POPULATIONS THAT ARE UNUSUALLY SUSCEPTIBLE .....	136
3.3 BIOMARKERS OF EXPOSURE AND EFFECT .....	138
3.3.1 Biomarkers of Exposure .....	139
3.3.2 Biomarkers of Effect .....	140

3.4	INTERACTIONS WITH OTHER CHEMICALS .....	141
CHAPTER 4. CHEMICAL AND PHYSICAL INFORMATION .....		145
4.1	CHEMICAL IDENTITY .....	145
4.2	PHYSICAL AND CHEMICAL PROPERTIES .....	145
CHAPTER 5. POTENTIAL FOR HUMAN EXPOSURE .....		147
5.1	OVERVIEW .....	147
5.2	PRODUCTION, IMPORT/EXPORT, USE, AND DISPOSAL .....	152
5.2.1	Production .....	152
5.2.2	Import/Export .....	154
5.2.3	Use .....	154
5.2.4	Disposal .....	155
5.3	RELEASES TO THE ENVIRONMENT .....	156
5.3.1	Air .....	157
5.3.2	Water .....	158
5.3.3	Soil .....	160
5.4	ENVIRONMENTAL FATE .....	161
5.4.1	Transport and Partitioning .....	161
5.4.2	Transformation and Degradation .....	167
5.5	LEVELS IN THE ENVIRONMENT .....	171
5.5.1	Air .....	172
5.5.2	Water .....	172
5.5.3	Sediment and Soil .....	174
5.5.4	Other Media .....	176
5.6	GENERAL POPULATION EXPOSURE .....	180
5.7	POPULATIONS WITH POTENTIALLY HIGH EXPOSURES .....	193
CHAPTER 6. ADEQUACY OF THE DATABASE .....		198
6.1	Information on Health Effects .....	198
6.2	Identification of Data Needs .....	201
6.3	Ongoing Studies .....	208
CHAPTER 7. REGULATIONS AND GUIDELINES .....		209
CHAPTER 8. REFERENCES .....		211
APPENDICES		
APPENDIX A. ATSDR MINIMAL RISK LEVEL WORKSHEETS .....		A-1
APPENDIX B. LITERATURE SEARCH FRAMEWORK FOR MIREX AND CHLORDECONE .....		B-1
APPENDIX C. USER'S GUIDE .....		C-1
APPENDIX D. QUICK REFERENCE FOR HEALTH CARE PROVIDERS .....		D-1
APPENDIX E. GLOSSARY .....		E-1
APPENDIX F. ACRONYMS, ABBREVIATIONS, AND SYMBOLS .....		F-1



## LIST OF FIGURES

1-1. Graph of Health Effects Found in Animals Following Oral Exposure to Mirex.....	2
1-2. Graph of Health Effects Found in Animals Following Oral Exposure to Chlordecone .....	4
1-3. Summary of Sensitive Targets of Mirex – Oral.....	10
1-4. Summary of Sensitive Targets of Chlordecone – Oral.....	11
2-1. Overview of the Number of Studies Examining Mirex Health Effects.....	17
2-2. Overview of the Number of Studies Examining Chlordecone Health Effects .....	18
2-3. Levels of Significant Exposure to Mirex – Oral.....	48
2-4. Levels of Significant Exposure to Chlordecone – Oral .....	71
3-1. Proposed Metabolic Pathways for Chlordecone.....	131
5-1. Number of NPL Sites with Mirex Contamination.....	147
5-2. Number of NPL Sites with Chlordecone Contamination .....	148
6-1. Summary of Existing Health Effects Studies on Mirex By Route and Endpoint .....	199
6-2. Summary of Existing Health Effects Studies on Chlordecone By Route and Endpoint.....	200

## LIST OF TABLES

1-1. Minimal Risk Levels (MRLs) for Mirex .....	10
1-2. Minimal Risk Levels (MRLs) for Chlordecone.....	12
2-1. Results of Epidemiological Studies Evaluating Associations Between Mirex and Health Outcomes	19
2-2. Results of Epidemiological Studies Evaluating Associations Between Chlordecone and Health Outcomes .....	25
2-3. Levels of Significant Exposure to Mirex – Oral.....	28
2-4. Levels of Significant Exposure to Chlordecone – Oral .....	53
2-5. Levels of Significant Exposure to Mirex – Dermal.....	76
2-6. Levels of Significant Exposure to Chlordecone – Dermal .....	77
2-7. <i>In Vivo</i> Genotoxicity of Mirex and Chlordecone in Orally-Exposed Animals.....	110
2-8. Genotoxicity of Mirex and Chlordecone <i>In Vitro</i> .....	111
4-1. Chemical Identity of Mirex and Chlordecone .....	145
4-2. Physical and Chemical Properties of Mirex and Chlordecone .....	146
5-1. Concentrations of Mirex in Aquatic Organisms.....	163
5-2. Lowest Limit of Detection for Mirex Based on Standards .....	171
5-3. Lowest Limit of Detection for Chlordecone Based on Standards .....	171
5-4. Geometric Mean and Selected Percentiles of Mirex (Lipid Adjusted) Serum Concentrations (in ng/g of Lipid or Parts per Billion on a Lipid-Weight Basis) for the U.S. Population from the National Health and Nutrition Examination Survey (NHANES) 1999–2004 .....	183
5-5. Weighted Arithmetic Mean and Unadjusted Standard Error of Mirex (Lipid Adjusted) Pooled Serum Concentrations (in ng/g of Lipid or Parts per Billion on a Lipid-Weight Basis) for the U.S. Population from the National Health and Nutrition Examination Survey (NHANES) 2005–2010 .....	185
5-6. Geometric Mean and Selected Percentiles of Mirex (Whole Weight) Serum Concentrations (in ng/g of Serum or Parts per Billion) for the U.S. Population from the National Health and Nutrition Examination Survey (NHANES) 1999–2004 .....	188
5-7. Weighted Arithmetic Mean and Unadjusted Standard Error of Mirex (Whole Weight) Pooled Serum Concentrations (in ng/g of Serum or Parts per Billion) for the U.S. Population from the National Health and Nutrition Examination Survey (NHANES) 2005–2010 .....	190

7-1. Regulations and Guidelines Applicable to Mirex and Chlordecone..... 209